Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes FailsCristiana Sessa, Nicoletta Colombo, Giuseppe Curigliano et al.|Journal of Clinical Oncology|2005Cited by 164
Abstract LB-302: A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumorsJean‐Charles Soria, Luca Gianni, Christophe Massard et al.|Cancer Research|2008Cited by 8
Phase I dose-finding study of trabectedin (T) in combination with cisplatin (C) in patients (pts) with advanced solid tumors.C. Sessa, Luca Gianni, Antonella Perotti et al.|Journal of Clinical Oncology|2011Cited by 0